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OBJECTIVE: The purpose of this study was to compare aerobic function [anaerobic threshold (% _VO2-AT),
respiratory compensation point (% _VO2-RCP) and peak oxygen uptake ( _VO2peak)] between physically active patients
with HIV/AIDS and matched controls and to examine associations between disease status, poor muscle strength,
depression (as estimated by the profile of mood states questionnaire) and the aerobic performance of patients.
METHODS: Progressive treadmill test data for % _VO2-AT (V-slope method), RCP and ( _VO2peak) were compared
between 39 male patients with HIV/AIDS (age 40.6¡1.4 years) and 28 male controls (age 44.4¡2.1 years) drawn
from the same community and matched for habitual physical activity. Within-patient data were also examined in
relation to CD4+ counts (nadir and current data) and peak isokinetic knee torque.
RESULTS: AT, RCP and ( _VO2peak) values were generally similar for patients and controls. Within the patient sample,
binary classification suggested that AT, RCP and ( _VO2peak) values were not associated with either the nadir or
current CD4+ count, but treadmill test variables were positively associated with peak isokinetic knee torque.
CONCLUSION: The aerobic performance of physically active patients with HIV/AIDS is generally well conserved.
Nevertheless, poor muscle strength is observed in some HIV/AIDS patients, which is associated with lower anaerobic
power and ( _VO2peak), suggesting the possibility of enhancing the aerobic performance of patients with weak
muscles through appropriate muscle-strengthening activities.
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& INTRODUCTION
The acute phase of HIV/AIDS is frequently marked by a
substantial loss of physical fitness. In planning an appro-
priate course of rehabilitation, it is important to know which
aspects of fitness deteriorate and the persistence of this
functional loss following treatment. Most studies have
pointed to a loss of muscular strength, with little deteriora-
tion of cardio-respiratory fitness (1-2). Nevertheless, some
reports have also indicated adverse effects of the disease
and treatment with non-nucleoside reverse transcriptase
inhibitors on various aspects of cardio-respiratory health.
Reported changes include delayed heart rate recovery
following exercise (3), increased cardiovascular risk factors
(particularly the HDL/LDL cholesterol ratio, secondary to
decreased plasma adiponectin levels) (4-5), deteriorating
endothelial function (6), atherosclerosis progression (7) and
increased risk of myocardial infarction (8).
Aerobic exercise has been recommended for patients with
HIV/AIDS, both as a possible means of slowing disease
progression [with benefits observed by Mustafa et al. (9),
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but not by Stringer et al. (10) or Terry et al. (11)] and also for
exercise’s potential to reverse the depressed mood that
commonly accompanies both HIV/AIDS infection and
highly active antiretroviral therapy (HAART) treatment
[with elevations of mood state reported by Ciccolo et al. (12),
Neidig et al. (13) and Stringer et al. (10), but not by Terry
et al. (11)].
In most reports to date, any changes in an individual’s
muscular strength have been considered independently of
peak aerobic power. However, this interpretation is not
entirely appropriate. The peak oxygen intake that a patient
can attain partially depends upon the muscle mass that is
activated by the test exercise (14). Furthermore, if the
muscles are weak, perfusion of the active tissues is
restricted, and lactate begins to accumulate at a low power
output, causing local fatigue and limiting the peak effort
that can be developed (15,16).
To shed further light upon these issues, we took a
substantial sample of physically active male patients with
HIV/AIDS and compared their aerobic performance with
matched control subjects from the same milieu. We also
compared values for subsets of the patient sample classified
in terms of immune status, exposure to retroviral treatment
and current peak isokinetic muscle torque. Our primary
hypotheses were that aerobic function would generally be
well maintained in physically active patients with HIV/AIDS
but that even within a sample engaged in regular endurance
activity, aerobic performance might nevertheless be impaired
in individual patients with substantial muscle weakness.
& METHODS
Volunteers
The patient sample consisted of 39 physically active males
living with HIV/AIDS. All were volunteers who were
recruited from an ambulatory outpatient clinic. The 28
matched controls were drawn from the same city. All
subjects were informed about the procedures and risks
before giving written consent to participate in the study,
which had been approved by the research ethics committee
of the Sa˜o Paulo University Hospital (File reference 768/06).
The protocol met all of the ethical standards established for
this journal (17).
An initial telephone call was used to invite 56 volunteers
with HIV/AIDS for a screening that focused on their current
health status, current drug and cigarette consumption and
physical activity. This was followed by a hospital visit for a
detailed history and physical examination covering pre-
vious and current health status and other tests that included
a 12-lead electrocardiogram, questionnaires regarding mood
state and ability to perform the basic and instrumental
activities of daily living, measures of body composition and
routine blood and urine tests. Criteria for exclusion
included the following: (1) acute or chronic psychological
disturbances; (2) central or peripheral nervous system
disorders; (3) musculo-skeletal problems; (4) cardiopulmon-
ary or metabolic disorders; (5) cigarette smoking; (6) surgery
or bed rest in the previous three months; and (7) any
orthopedic conditions that could limit exercise testing or be
exacerbated by exercise testing. Thirty-nine of the 56
volunteers met the criteria for the definitive study.
Infection had been acquired through homosexual or
heterosexual intercourse in 32 of the 39 patients; in the
remainder of the patients, the source of infection was
intravenous drug use or blood transfusion. The mean
duration of diagnosed infection was 6.1¡0.8 years, with
20 of the 39 patients developing AIDS within 6.0¡0.9 years.
HAART had been administered to 18 of the 39 patients for
an average of 56.1¡7.5 months, with an adherence of
9.2¡0.3 on a 0 to 10 scale.
The control group met the same health criteria as the
patients, with the exception that the former were HIV-
negative. The two groups were also matched in terms of
their age, physical activity level and body mass index.
Body composition and habitual physical activity
Height and body mass were determined by standard
anthropometric techniques. Adiposity was determined using
Harpenden skinfold calipers (Baty International, Burgess
Hill, West Sussex, UK); central adiposity was represented by
the sum of subscapular, mid-axillary, abdominal and
suprailiac skinfolds, and peripheral adiposity was repre-
sented by the sum of the biceps, triceps, anterior thigh and
mid-calf skinfolds.
A Portuguese version of the international physical activity
questionnaire (IPAQ) was used to estimate habitual physical
activity (18,19). Subjects reported the frequency and dura-
tion of walking (considered light activity) and bouts of
moderate and vigorous physical activity. The information
was combined to yield an approximate physical activity
score, measured in kJ of energy expended per week. For
each of the light [3.3 METs], moderate [4.0 METs] and
vigorous [8.0 METs] activities, the duration (minutes per
day) was multiplied by the reported frequency (days per
week) to yield accumulated totals of MET-min week-1.
Cardiopulmonary parameters
Peak oxygen uptake ( O2peak) was measured directly
using a progressive treadmill protocol (20,21). An auto-
mated gas analyzer (CPX/D, Medgraphics, Saint Paul, MN),
calibrated against room air and a medically certified gas
mixture of 11.9% O2 and 5.12% CO2, provided breath-by-
breath data on respiratory gas exchange. A 12-lead electro-
cardiogram was monitored continuously during testing.
Exercise began at a walking velocity of 3.6 km h-1 and with a
1% gradient. The velocity was increased by 1.2 km h-1 in
each succeeding minute until volitional exhaustion. O2peak
was recorded when one or more of the following criteria
were satisfied: 1) respiratory exchange ratio (RER) $1.10; 2)
attainment of the age-predicted maximal heart rate; 3)
volitional fatigue; and/or 4) signs of exhaustion (unsteady
gait, hyperpnea, sweating, facial flushing and grimacing)
(2). The test-retest error of peak oxygen intake determina-
tions was ,5%. A computerized regression analysis
determined the anaerobic threshold (AT) from a plot of
CO2 intake ( CO2) versus O2 intake ( O2) and the onset of
excess CO2 output (V-slope method). The respiratory
compensation point (RCP) was detected by plotting respira-
tory minute ventilation against CO2.
Peak muscle torque
Peak muscle torque was evaluated using an isokinetic
dynamometer (Biodex Multi-Joint System, Shirley, NY).
This apparatus was calibrated weekly, according to the
manufacturer’s instructions. After one familiarization test,
volunteers performed five definitive maximal extensor
movements at an angular velocity of 60 ?˚s-1, with verbal
encouragement throughout; a two-minute rest interval was
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allowed between sets. The largest of the five readings was
noted as the individual’s peak torque [Nm].
Blood collection, leukocyte counts and flow
cytometry
Subjects refrained from ingesting solid or liquid food
containing caffeine or chocolate or cola-based products and
avoided even moderate physical activity for 48 hours before
blood sampling. The subjects arrived at the laboratory at
7:00 a.m., having fasted overnight, and blood was collected
from the median antecubital vein after 30 min of seated rest.
Differential leukocyte counts were performed using an
automated Cell-Dyn 3500 analysis system (Coulter Corp.,
Miami, FL).
For the flow cytometry, 200 mL of whole blood was
incubated with 5 mL of appropriate monoclonal antibodies
(CD4+, CD8+ [Becton-Dickinson, Miami, FL]) for 20 minutes
in the dark and at room temperature. Samples with isotypic
control antibodies (IgG1[FITC]/IgG1[PE]/IgG1[PCy-5])
were run in parallel with each sample. A minimum of
5000 cells was analyzed on the Coulter XL-MCL counter
(Coulter Corp., Miami, FL) using XL System II software
(Coulter Corporation, Miami, FL). The lowest recorded
CD4+ count was considered the CD4+ nadir.
Statistical analysis
All analyses were performed using the Predictive
Analytics Software 17.0 for Windows Package (PASW,
Table 1 - Characteristics of controls and patients (classified by CD4+ nadir).
Control (n = 28) Individuals living with HIV/AIDS
CD4+ nadir (cells?mm-3)
, 200 (n =17) $ 200 (n= 22) Total (n = 39)
Age (years) 44.4¡2.1 41.9¡1.9 39.6¡2.0 40.6¡1.4
Body height (m) 1.74¡0.1 1.69¡0.2 1.73¡0.1 1.71¡0.1
Body composition —————————————————————
Body mass (kg) 80.1¡1.21 71.6¡2.9 74.0¡2.5 72.9¡1.9
BMI (kg?m-2) 26.4¡0.4 24.8¡0.8 24.8¡0.9 24.8¡0.6
CBA (mm) ___ 52.2¡5.0 71.4¡8.0 63.0¡5.2
PBA (mm) ___ 24.9¡2.4 30.8¡3.9 28.2¡2.4
TBA (mm) ___ 77.1¡6.9 102.3¡11.3 91.2¡7.2
HA (MET.min.week-1) 1797¡56 1589¡229 1726¡188 1666¡144
Immunological parameters ————————————
CD4+ (cells?mm-3) 433¡67 588¡902 521¡59
CD8+ (cells?mm-3) 1083¡111 1086¡167 1084¡105
CD4+ nadir (cells?mm-3) 154¡36 344¡482 261¡34
Viral load (log) 4.1¡0.3 4.5¡0.2 4.4¡0.2
Values are means ¡ standard errors of mean; BMI: body mass index; CBA: central body adiposity; PBA: peripheral body adiposity; TBA: total body
adiposity; HA: habitual activity;
1Statistically significant difference between control and HIV/AIDs group with CD4+,200 cells?mm-3 (p,0.05); 2Statistically significant difference between
HIV+ CD4+,200 cells?mm-3 and HIV+ CD4+$200 cells?mm-3 (p,0.05).
Table 2 - Findings during progressive treadmill (TM) test for controls and patients (classified by CD4+ nadir). Shaded
areas indicate statistically significant differences.
Individuals living with HIV/AIDS
CD4+ nadir (cells?mm-3)
Control(a) (n =28) , 200(b) (n = 17) $200(c) (n = 22) Total (n = 39)
HR (bpm) __ _____________
AT 119¡3 120¡3 122¡3 121¡2
RCP 140¡3 141¡4 147¡3 144¡2
PHR 179¡3 178¡4 179¡2 178¡2
RPE __ _____________
AT 8.5¡0.2 8.8¡¡0.2 9.2¡0.3 9.0¡0.2
RCP 11.9¡0.3 11.8¡0.4 12.2¡0.3 12.0¡0.3
O2 (mL?kg
-1?min-1) __ _____________
AT 16.4¡0.5 17.4¡0.5 17.5¡0.6 17.5¡0.4
RCP 22.6¡0.7 24.3¡1.0 23.2¡0.9 23.7¡0.7
Peak 32.2¡0.9 34.6¡1.4 33.9¡1.2 34.2¡0.9
O2 (% peak) __ _____________
AT 51.3¡1.6 50.3¡1.5 52.3¡2.0 51.4¡1.3
RCP 70.5¡1.8 70.8¡2.0 68.6¡2.3 69.6¡1.6
TM test duration (min) 6.7¡0.2 9.5¡0.5 9.6¡0.6 9.6¡0.4
Peak isokinetic torque (Nm?kg-1) __ 242¡11 253¡11 248¡8
p,0.05; Values are means¡ standard errors of mean; AT: anaerobic threshold; RCP: respiratory compensation point; V
:
O2: oxygen intake; HR: heart rate;
PHR: peak heart rate; RPE: rating of perceived exertion; Statistically significant difference between control and HIV+ subgroups.
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Inc., Chicago, IL). Kolmogorov-Smirnov statistics demon-
strated that all data were normally distributed. Data are
presented as the means ¡ standard errors of the mean.
Unpaired Student t-tests were used to compare patients and
control groups and also to compare patient subgroups.
Univariate regression analyses also investigated associa-
tions of peak isokinetic torque with anaerobic threshold,
respiratory compensation point and O2 peak. Statistical
significance was set at p,0.05 throughout.
We determined that a 10% loss of aerobic performance
would have practical and clinical significance. Thus, the
sample size of 39 patients and 28 controls provided
adequate sample power to detect such an effect at the 95%
confidence level. This remained true with binary subdivi-
sion of the 39-patient sample.
& RESULTS
General characteristics and immunological data for the
patients and control subjects are summarized in Table 1. The
patients tended to have a slightly lower body mass than the
controls, particularly in the subgroup with a lower CD4+
nadir, but the patients did not differ significantly from the
controls in terms of age or body mass index. In terms of
Table 3 - Findings during progressive treadmill (TM) test and strength measurements for patients (classified by current
CD4+ count, cells?mm-3). Shaded area indicates statistically significant differences.
Individuals living with HIV/AIDS
Current CD4+,200 cells mm-3 (n = 6) Current CD4+$200 cells mm-3 (n = 33)
HR (bpm) ________________
AT 115¡2 (107-120) 122¡3 (94-156)
RCP 134¡5 (122-157) 146¡3 (116-178)
PHR 172¡8 (136-191) 179¡2 (161-203)
RPE ________________
AT 8.8¡0.3 (8.0-10.0) 9.0¡0.2 (7.0-12.0)
RCP 11.5¡0.9 (9.0-15.0) 12.1¡0.3 (9.0-15.0)
O2 (mL?kg
-1?min-1) ________________
AT 16.5¡1.3 (11.4-20.1) 17.6¡0.4 (13.4-22.5)
RCP 21.6¡1.8 (15.4-28.7) 24.0¡0.7 (16.4-31.7)
Peak 32.5¡3.3 (20.1-41.7) 34.4¡0.9 (25.2-43.4)
O2 (% peak) ________________
AT 51.7¡3.0 (41.0-59.0) 51.5¡1.4 (40.9-79.0)
RCP 67.8¡4.0 (53.0-77.0) 70.1¡1.7 (52.0-92.0)
TM test duration (min) 8.3¡0.9 (4.0-10.0) 9.8¡0.4 (6.0-20.0)
Peak isokinetic torque (Nm?kg-1) 205¡13 (151-241) 257¡8 (150-349)*
*p,0.05; Values are means¡ standard errors of mean; AT: anaerobic threshold; RCP: respiratory compensation point; V
:
O2: oxygen intake; HR: heart rate;
PHR: peak heart rate; RPE: rate of perceived exertion.
Table 4 - Findings during progressive treadmill (TM) test and strength measurements for patients (classified by peak
muscle torque at 60o?sec-1). Shaded areas indicate statistically significant differences.
Peak isokinetic torque (Nm?kg-1)
,230 (n = 15) $230 (n = 24)
TM Velocity (km?h-1)
AT 5.4¡0.2 (3.6-7.2) 6.0¡0.2 (4.8-7.2)*
RCP 7.3¡0.2 (6.0-8.4) 8.3¡0.2 (6.0-10.8)*
PEAK 11.3¡0.6 (7.2-15.6) 13.4¡0.4 (9.6-18.0)*
HR (bpm) ________________
AT 122¡4 (94-145) 120¡3 (94-156)
RCP 142¡3 (125-159) 145¡3 (116-178)
PHR 174¡3 (136-195) 180¡3 (161-203)
RPE ________________
AT 9.1¡0.3 (7.0-12.0) 9.0¡0.2 (7.0-12.0)
RCP 11.9¡0.5 (9.0-15.0) 12.0¡0.3 (9.0-15.0)
O2 (mL?kg
-1?min-1) ________________
AT 15.9¡0.7 (11.4-20.0) 18.3¡0.4 (15.1-22.5)*
RCP 20.6¡0.7 (15.4-23.8) 25.4¡0.7 (18.4-31.7)*
Peak 29.8¡1.2 (20.1-40.0) 36.6¡0.9 (27.7-43.4)*
O2 (% peak) ________________
AT 54.2¡2.7 (41.0-79.0) 49.9¡1.2 (40.9-67.0)
RCP 70.0¡2.9 (53.0-92.0) 69.6¡1.8 (52.0-87.0)
TM test duration (min) 9.0¡0.5 (4.0-13.0) 9.9¡0.6 (6.2-20.0)
HA (MET.min.week-1) 1667¡222 (714-3999) 1665¡193 (747-3839)
Peak isokinetic torque (Nm?kg-1) 203¡7 (150-229) 277¡7 (231-349)*
*p,0.05; values are means¡ standard errors of mean; AT: anaerobic threshold; RCP: respiratory compensation point; V
:
O2: oxygen intake; HR: heart rate;
PHR: peak heart rate; RPE: rating of perceived exertion; HA: habitual activity.
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reported activity, both groups were quite active, under-
taking the equivalent of 60 minutes or more of moderate
activity (4 METS) per day. The average peak isokinetic
extensor torque of the patients (248¡8 Nm) was similar to
previously reported values for healthy subjects in this age
group (21-27).
Findings during the progressive treadmill test are
summarized in Table 2. Patients and control subjects
reached similar peak heart rates, which were relatively high
for their age, but the peak oxygen intake values were not
outstanding in either group. There was no evidence that the
AT, RCP or ( O2peak) was any lower in the patients than in
the control subjects, irrespective of the patients’ CD4+ nadir.
A similar analysis in terms of whether the patients had
received HAART revealed no differences in this subgroup
(data not shown).
Classification of patients based on their current CD4+
counts (Table 3) again revealed no statistically significant
differences, with the exception of peak isokinetic torque,
which was approximately 20% less in those individuals with
a count ,200 cells.mm-3.
However, when patients were classified in terms of their
peak isokinetic torque (Table 4), the AT, RCP and peak
aerobic power were all significantly greater in those
individuals with well-preserved muscular strength; stron-
ger subjects were able to progress to a significantly greater
treadmill velocity. Linear regression analysis revealed
parallel trends among individual subjects (Figure 1); AT
and RCP exhibited statistically positive associations with
peak isokinetic torque.
& DISCUSSION
Our data confirm our initial hypothesis: on average, the
( O2peak) of physically active individuals with HIV/AIDS
does not differ from that of control subjects of similar age
and with similar physical activity patterns. This is in
agreement with previous reports, which have also sug-
gested that after treatment, the cardio-respiratory fitness of
physically active individuals with HIV/AIDS generally
shows little deterioration (1-2). Nevertheless, our findings
also underline that within this apparent normality of aerobic
function, individual patients who have substantial muscle
strength deficiency also exhibit substantial deficiency of
aerobic performance, averaging around 20%, relative to
equally active but stronger peers.
Because our analysis was cross-sectional, it might be
argued that the individuals who developed a low peak
isokinetic torque had engaged in less habitual activity
during their leisure time or were simply less motivated
during exercise testing. The first of these explanations can
be largely discounted because the reported activity levels of
the two subgroups were equal. The small and statistically
non-significant trend to a lower peak heart rate (Table 4)
and some association between a poor aerobic performance
and high depression scores, as measured by the profile of
mood states questionnaire (data not shown), may signal
somewhat poorer motivation in those who were depressed.
Nevertheless, it seems of importance that lower muscle
strength was also linked to a lower current CD4+ count
(Table 2). Moreover, although differences in motivation
might have influenced the peak oxygen intake, it is not as
easy to explain the lower ATs of the weaker individuals
(Table 4) simply in terms of differences in individual
motivation. A direct effect of local muscle strength upon
perfusion of the limbs and, thus, peak oxygen transport
offers a more plausible explanation (14). Therefore, we
Figure 1 - Relationship between peak muscle torque (Nm?kg-1) and
V
:
O2 at (A) the anaerobic threshold, (B) the respiratory compensa-
tion point and (C) the peak oxygen intake (mL?kg?-1min-1).
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conclude that an HIV/AIDS-induced reduction in muscle
mass and the resultant loss of muscle strength appears to
impair both anaerobic effort (by causing lactate to accumu-
late at a lower fraction of maximal oxygen intake) (15) and
( O2peak) (because of both earlier fatigue and the lower
volume of muscle that is available for activation during
treadmill testing) (14).
There are a number of limitations to our data.
Unfortunately, we were unable to obtain strength data for
the control subjects, but the average values observed in the
patients were not much lower than those reported in
previous normal studies (22-27). It could also be objected
that with greater opportunity to practice procedures, higher
test scores might have been obtained on both the treadmill
and the dynamometer tests; however, this in no way
invalidates the differences we have observed between
patients with high and low muscular strength values. It
should also be emphasized that our patient sample was
male, and the sample was deliberately selected in terms of a
number of criteria for good health; the sample represented
approximately one-sixth of patients attending the HIV/
AIDS clinic. It would be interesting to extend our observa-
tions by assessing the effects of muscle weakening upon
aerobic function in an unselected group of HIV/AIDS
patients, including women and men.
The practical clinical implications of our findings point to
the following: to ensure good aerobic power in patients with
HIV/AIDS, rehabilitation should include a program of
progressive muscle strengthening exercises, and such
rehabilitation should be continued until the strength of the
major muscle groups has been normalized. This proposal
now needs to be tested with a group of HIV/AIDS patients
with aerobic impairment secondary to poor muscle strength
by evaluating how far the patients’ aerobic power can
indeed be enhanced by a program that normalizes muscular
function.
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